Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05451849 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
A Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by TCR2 Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 7
- Study locations
NCT05451849 is a Phase 1 study of Colorectal Cancer and Ovarian Cancer that is active but no longer recruiting, run by TCR2 Therapeutics. The registered enrollment target is 6 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (100% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT05451849, a Phase 1 study of Colorectal Cancer and Ovarian Cancer, is active but no longer recruiting, sponsored by TCR2 Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 7
- Study locations
Study Summary
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex and second, a PD-1:CD28 switch receptor, which is expressed on the surface of the T cell, independently from the TCR. The PD-1:CD28 switch receptor comprises the PD-1 extracellular domain fused to the CD28 intracellular domain via a transmembrane domain. Thus, the switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL TC-510
Study Locations (7)
California
- University of California, San Francisco - San Francisco
Florida
- University of Miami - Miami
Maryland
- National Cancer Institute - Bethesda
Minnesota
- University of Minnesota, Masonic Cancer Center - Minneapolis
New York
- Montefiore Einstein Cancer Center - The Bronx
Oklahoma
- University of Oklahoma - Oklahoma City
Tennessee
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2028-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05451849
The ClinicalTrials.gov registry entry for NCT05451849 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (100% lower). The listed sponsor is TCR2 Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT05451849 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT05451849 about?
NCT05451849 is a clinical study titled "A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer". TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell recepto...
What is the current status of trial NCT05451849?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-06-21. Estimated completion is 2028-10-30.
What conditions does trial NCT05451849 study?
This clinical trial studies the following conditions: Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer, Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT05451849?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), TC-510 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05451849?
This trial is sponsored by TCR2 Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05451849 being conducted?
This trial has 7 study locations across California, Florida, Maryland, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.